A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Eli Lilly and Company
Merck Sharp & Dohme LLC
Toray Industries, Inc
Stanford University
Washington University School of Medicine